The timeline:

• Until 30 January 2023, clinical trial sponsors can choose whether to submit an initial clinical trial application in line with the Clinical Trials Directive (EC) No. 2001/20/EC or via CTIS.
• From 31 January 2023, submission of initial clinical trial applications via CTIS becomes mandatory.
• By 31 January 2025, all ongoing trials approved under the Clinical Trials Directive No. 2001/20/EC will be governed by the new Regulation and must be transitioned to CTIS.

Revised Q&A document:

Matching the timeline, the EMA published a revised version 6.2 of the Q&A on the new clinical trial regulation, as well as descriptive material and YouTube videos on the subject.

New is

• Q&A 1.24 How are patient facing documents expected to be
  submitted?

Revised are:

• Q&A 2.6 (point 94.) Chapter X and Annex VI of the Clinical Trials
  Regulation refer to the content of the labelling of the investigational
  medicinal product (IMP). Does this mean a mock-up needs to be
  submitted?
• Q&A 3.8 (point 171.) How should a sponsor proceed when a substantial
  modification is related to a document common to various clinical trials of
  the same sponsor and same IMP?
• Chapter 11 was updated regarding the arrangements for the transitional periods and the language requirements for part I documents.

Sources:

EC: New Clinical Trial Regulation (EU) 536/2014
EMA: Clinical Trials Information System
EMA: Clinical Trials Regulation
EMA: Q&A